[Measurement of 75Se-SeHCAT abdominal retention in the initial diagnosis of Bile Acid Absorption (BAM)]

Rev Esp Med Nucl. 2011 Sep-Oct;30(5):297-300. doi: 10.1016/j.remn.2011.03.007. Epub 2011 Apr 27.
[Article in Spanish]

Abstract

Aim: To evaluate the usefulness of the (75)SeHCAT abdominal retention (AR) measurement in the early diagnosis of diarrhea syndrome (DS).

Methods: Thirty-seven patients with diarrhea syndrome within the first month of evolution were prospectively evaluated. The (75)Se-SeHCAT abdominal retention was measured 4 and 7 days post-administration of 0.01 mCi of (75)SeHCAT. The test was performed prior to treatment and at 3 months when the baseline study was positive. The test was considered positive if the RA was <25% at 4(th) and <10% on the 7th day. The patients were visited at 3 months. Depending on the response, 3 groups were established: a) complete response: normalization of stool frequency, b) partial response, decrease of frequency or c) no response.

Results: Group A: The AR of (75)Se-SEHCAT was normal in 21 patients. Six were diagnosed of colonic diverticulosis, 8 of irritable bowel syndrome, 1 of lymphocytic colitis, 1 of post-gastroenteritis syndrome, 1 of celiac disease and 1 of stenosis of the cardia. Four are still under study. Group B: The AR of (75)Se-SEHCAT decreased in 16 patients. All showed abnormal AR at day 7 and all but 1 at day 4. Following administration of cholestyramine resin, 8 (50%) presented partial response and 8 (50%) complete response. At 3 months, AR had increased at day 4 and 9 at day 7.

Conclusion: The measurement of (75)SEHCAT abdominal retention allows the early diagnosis of bile acid malabsorption in 43% of the patients with DS. Measurement at 7 days seems more accurate than that at 4 days.

Publication types

  • Clinical Trial

MeSH terms

  • Abdomen / diagnostic imaging
  • Adult
  • Aged
  • Aged, 80 and over
  • Anticholesteremic Agents / therapeutic use
  • Cardia / pathology
  • Celiac Disease / complications
  • Celiac Disease / diagnosis
  • Cholestyramine Resin / therapeutic use
  • Chronic Disease
  • Colitis, Lymphocytic / complications
  • Colitis, Lymphocytic / diagnosis
  • Constriction, Pathologic
  • Diarrhea / diagnosis
  • Diarrhea / diagnostic imaging*
  • Diarrhea / drug therapy
  • Diarrhea / etiology
  • Diarrhea / metabolism
  • Diverticulosis, Colonic / complications
  • Diverticulosis, Colonic / diagnosis
  • Early Diagnosis
  • Female
  • Humans
  • Intestinal Absorption
  • Irritable Bowel Syndrome / complications
  • Irritable Bowel Syndrome / diagnosis
  • Malabsorption Syndromes / diagnostic imaging*
  • Malabsorption Syndromes / etiology
  • Male
  • Middle Aged
  • Prospective Studies
  • Radionuclide Imaging
  • Radiopharmaceuticals* / pharmacokinetics
  • Selenium Radioisotopes* / pharmacokinetics
  • Taurocholic Acid / analogs & derivatives*
  • Taurocholic Acid / pharmacokinetics
  • Tissue Distribution

Substances

  • Anticholesteremic Agents
  • Radiopharmaceuticals
  • Selenium Radioisotopes
  • Cholestyramine Resin
  • Taurocholic Acid
  • 23-seleno-25-homotaurocholic acid